🧪
hypothesis

Exosomal α-Synuclein as an Interneuronal Propagation Vector in Parkinson's Disease

Hypothesis

Exosomal α-Synuclein as an Interneuronal Propagation Vector in Parkinson's Disease

Misfolded α-synuclein aggregates are transmitted via exosomes from donor to recipient neurons, templating endogenous aSyn misfolding through a 'prion-like' mechanism that explains Braak staging progression patterns.
🧬 RAB27A🩺 neurodegeneration🎯 Composite 60%💱 $0.55▼7.2%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 4 support 5 oppose
✓ All Quality Gates Passed
Mechanistic 0.72 (15%) Evidence 0.75 (15%) Novelty 0.80 (12%) Feasibility 0.45 (12%) Impact 0.55 (12%) Druggability 0.40 (10%) Safety 0.35 (8%) Competition 0.65 (6%) Data Avail. 0.70 (5%) Reproducible 0.58 (5%) KG Connect 0.12 (8%) 0.595 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite60%

🧪 Overview

Misfolded α-synuclein aggregates are transmitted via exosomes from donor to recipient neurons, templating endogenous aSyn misfolding through a 'prion-like' mechanism that explains Braak staging progression patterns. This hypothesis is biologically plausible but causally unproven—the exosome field struggles to distinguish propagation vectors from secondary clearance mechanisms. Druggability is severely constrained by the essential physiological functions of exosomes (synaptic function, immune surveillance, waste removal). The essential-function problem makes therapeutic inhibition appear inherently risky. However, GBA modulation (ambroxol, venglustat) may address downstream aggregation, and LRRK2 inhibitors (DNL201, BIIB122) may reduce exosome release. The Skeptic revised confidence to 0.65; Domain Expert to 0.58, noting that alternative propagation mechanisms (tunneling nanotubes) may compensate for exosome blockade.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["RAB27A GTPase<br/>Vesicle Trafficking"]
    B["Synaptic Vesicle<br/>Exocytosis"]
    C["Neurotransmitter<br/>Release"]
    D["Cytoskeletal<br/>Remodeling"]
    E["Dense Core Vesicle<br/>Secretion"]
    F["Neuronal<br/>Communication"]
    G["RAB27A Mutations<br/>Neurodevelopmental Disease"]
    A --> B
    B --> C
    B --> D
    C --> F
    D --> F
    A --> E
    E --> F
    G --> A
    style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style G fill:#6a1b9a,stroke:#ce93d8,color:#ce93d8

⚖️ Evidence

⚖️ Evidence Matrix4 supports5 contradicts
Supports
Exosomal α-syn release demonstrated in PD models; PMID 20619448
PMID:20619448
Supports
Braak staging consistent with retrograde propagation pattern; PMID related
Supports
Exosome pathway genes (RAB27A, GBA) implicated in PD GWAS
Supports
Selective neuronal vulnerability patterns support propagation model; PMID 28641111
PMID:28641111
Contradicts
No direct demonstration that exosomal aSyn causes de novo aggregation in vivo
Contradicts
CSF exosome isolation protocols produce heterogeneous preparations—neuron-derived vs glial exosomes indistinguishable
Contradicts
LRRK2 inhibitors reducing exosome release have not demonstrated anti-PD efficacy in trials
Contradicts
Alternative propagation via tunneling nanotubes may compensate—insufficient as monotherapy
Contradicts
RAB27A knockout causes immune deficiency (Griscelli syndrome)—systemic inhibition unacceptable
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — RAB27A

No curated PDB or AlphaFold mapping for RAB27A yet. Search RCSB →

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for RAB27A →

No DepMap CRISPR Chronos data found for RAB27A.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 0.4%
Volatility
Low
0.0026
Events (7d)
2
Price History
▼7.2%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF patients with newly diagnosed Parkinson's disease (diagnosed <1 year) are stratified by baseline plasma exosome-associated α-synuclein concentration (high vs. low tertiles) AND followed longitudinaMean MDS-UPDRS Part III score increase ≥8 points in high tertile vs. ≤4 points in low tertile at 36 months— no observation —pending0.48
IF RAB27A expression is reduced by ≥70% in human iPSC-derived neurons (via CRISPRi or siRNA) AND these neurons are cocultured with α-synuclein preformed fibril (PFF)-seeded donor neurons for 14 days T≥50% reduction in recipient neuron phospho-α-synuclein (Ser129) aggregates relative to scramble control, measured by high-content imaging or ELISA— no observation —pending0.52
🔮 Falsifiable Predictions (2)
pendingconf 52%
IF RAB27A expression is reduced by ≥70% in human iPSC-derived neurons (via CRISPRi or siRNA) AND these neurons are cocultured with α-synuclein preformed fibril (PFF)-seeded donor neurons for 14 days THEN exosome release will be significantly reduced AND recipient neuron phospho-α-synuclein (Ser129)
Predicted outcome: ≥50% reduction in recipient neuron phospho-α-synuclein (Ser129) aggregates relative to scramble control, measured by high-content imaging or ELISA
Falsification: Recipient neuron phospho-α-synuclein levels show no significant difference between RAB27A knockdown and scramble control groups (p>0.05 by Mann-Whitney U test), indicating exosome blockade does not pr
pendingconf 48%
IF patients with newly diagnosed Parkinson's disease (diagnosed <1 year) are stratified by baseline plasma exosome-associated α-synuclein concentration (high vs. low tertiles) AND followed longitudinally for 36 months THEN the high-tertile group will demonstrate significantly faster motor progressio
Predicted outcome: Mean MDS-UPDRS Part III score increase ≥8 points in high tertile vs. ≤4 points in low tertile at 36 months
Falsification: No significant difference in motor progression rate between exosomal α-synuclein tertiles (p>0.05 for group × time interaction in mixed linear model), or inverse relationship where high baseline exoso
View on SciDEX ↗